Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early‐Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study

Tian, Wei; Wu, Min; Deng, Yongchuan

doi:10.1002/cpdd.420

Cited by 12 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, different AIs may have varying effects on blood lipids [32] and other safety concerns [33]. According to some studies, anastrozole is less toxic than exemestane and letrozole, consistent with previous reports [34]. AIs are associated with more CVD risk than tamoxifen [35].…”

Section: Discussionsupporting

confidence: 68%

Comparison of Changes in Lipid Profiles of Eastern Chinese Premenopausal Women with Early-Stage Breast Cancer Treated with Different Endocrine Therapy: A Retrospective Study

Wang¹,

Shen²,

Wu³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (especially ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids in young premenopausal breast cancer patients. Methods: This study enrolled 160 premenopausal patients with stage I-III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment, weight and height, and past medical history. They have no history of cardiovascular disease. The changes of blood lipids in the types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after the start of endocrine therapy. Generalized Linear Mixed Model (GLMM) was used in analyses Results: Our data revealed that LDL-C of patients with TAM group in the 6th, 12th, and 24th months was significantly lower than that in the 3rd month, while HDL-C in the 6th, 12th, and 24th months was significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C in the 24th month was significantly higher than that in the 3rd month, TC in the 24th month was significantly higher than that in the 6th month. The lipid profiles of OFS plus AI group did not show significant differences at any time point but were significantly higher than those of the other two groups.Conclusions: TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values at various time points was observed between TAM and TAM plus OFS groups. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size.

show abstract

Section: Discussionsupporting

confidence: 68%

Comparison of Changes in Lipid Profiles of Eastern Chinese Premenopausal Women with Early-Stage Breast Cancer Treated with Different Endocrine Therapy: A Retrospective Study

Wang¹,

Shen²,

Wu³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…LDL-C, HDL-C, HCY and UA levels were detected using direct methods, and the glycerol-phosphoric acid oxidase peroxidase method was used to measure the serum TG level. The cholesterol oxidase method was used to determine the serum TC level, as described previously[19].…”

Section: Methodsmentioning

confidence: 99%

Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study

Tian

Yao

Fan³

et al. 2019

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Many different treatments may affect the serum lipid profiles of breast cancer patients. This study analyzed serum lipid levels at different periods during treatment to observe the changes in lipid profiles during and after chemotherapy and to compare the different effects of different chemotherapy regimens on serum lipid profiles. A total of 805 patients were included in this study. We measured the lipid profiles of patients who received surgery without chemotherapy prior to the operation and at 3, 6 and 12 months after operation. In addition, in patients who underwent chemotherapy, the lipid profiles were measured prior to chemotherapy, prior to the last cycle of chemotherapy and 6 months after chemotherapy. Lipid profile measurements included total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), homocysteine (HCY), and uric acid (UA). (Neo)Adjuvant chemotherapy exerted an adverse temporary effect on lipid levels (manifested as increased TG and LDL-C levels, and decreased HDL-C levels, particularly in the adjuvant chemotherapy group) during the chemotherapy periods. However, this influence was not sustained, as the lipid profiles levels were generally restored to baseline levels 6 months after chemotherapy completion. Different age groups showed different changes in lipid levels that were influenced by chemotherapy. The younger group (20–40 years old) showed a greater increase in TC and LDL-C levels during chemotherapy than the 41-65-year-old group. Chemotherapy exerts an adverse temporary effect, and the effects of different regimens on lipid levels are similar. Furthermore, lipid profiles in younger women may be more sensitive to chemotherapy.

show abstract

“…1 Altered lipid profiles are considered as the likely means through which the relative risks for cardiovascular events increase in these patients. 2 Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study Third-generation AIs such as exemestane, letrozole, and anastrozole have proven to be more active than tamoxifen for postmenopausal women diagnosed with hormone receptor-positive breast cancer. 3 Consequently, AIs are frequently used as adjuvant therapy in patients with hormone receptor-positive breast cancer as per National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines.…”

Section: Introductionmentioning

confidence: 99%

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study

et al. 2020

View full text Add to dashboard Cite

Background: Aromatase inhibitors (AIs) influence blood lipid profiles. However, relatively few studies have directly compared the treatment effects of steroidal and nonsteroidal AIs. Methods: A prospective single-center cohort study was conducted to investigate the effects of steroidal and nonsteroidal AIs on lipid profiles during the first 24 months of endocrine therapy in hormone receptor-positive postmenopausal patients with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, while the secondary endpoints were changes in lipid profiles and lipid event-free survival. Results: Comparison of the lipid profiles of the two groups showed that triglycerides (TGs) and total cholesterol (TC) levels were significantly higher in the nonsteroidal AI group over 24 months ( p < 0.05), whereas low-density lipoprotein cholesterol (LDL-C) was significantly higher only at 3 months ( p = 0.017) and 6 months ( p = 0.026). High-density lipoprotein cholesterol (HDL-C) was significantly lower in the steroidal group at all time points ( p < 0.05), except at 18 months ( p = 0.085). The cumulative incidence of lipid events in the steroidal and nonsteroidal groups at 24 months was 25.3% and 37.0%, respectively. Multivariate analysis results indicated that TG, LDL-C, and steroidal AIs were independently associated with blood lipid events. Conclusion: This trial showed that a significantly higher cumulative incidence of lipid events occurred in the nonsteroidal AI group than in the steroidal AI group, which indicated that steroidal AIs exerted a protective effect against blood lipid events in postmenopausal women receiving an AI as adjuvant therapy for breast cancer. ClinicalTrials.gov identifier: NCT02765373

show abstract

Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early‐Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study

Cited by 12 publications

References 25 publications

Comparison of Changes in Lipid Profiles of Eastern Chinese Premenopausal Women with Early-Stage Breast Cancer Treated with Different Endocrine Therapy: A Retrospective Study

Comparison of Changes in Lipid Profiles of Eastern Chinese Premenopausal Women with Early-Stage Breast Cancer Treated with Different Endocrine Therapy: A Retrospective Study

Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study

Contact Info

Product

Resources

About